## STZ: Constellation Brands, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($132.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Constellation Brands, Inc. Schedules Third Quarter Financial Results Announcement and Conference Call for January 2026**
- Source: Quiver Quantitative | 20251204T221508 | Neutral | Relevance: 100%
- Constellation Brands, Inc. (NYSE: STZ) will announce its third-quarter financial results for the period ending November 30, 2025, on January 7, 2026, after market close. A conference call with CEO Bill Newlands and CFO Garth Hankinson will follow on January 8, 2026, at 10:30 a.m. ET, accessible by phone or webcast. The company highlights its market position as a leading beverage alcohol company and commitment to sustainability.

**2. Total debt per share of Constellation Brands, Inc. Class A â€“ LS:871918**
- Source: TradingView | 20251203T230625 | Neutral | Relevance: 100%
- This page displays financial data for Constellation Brands, Inc. Class A (LS:871918), specifically focusing on its total debt per share. It provides market information from Lang & Schwarz Tradecenter and indicates that the market is currently closed. While the data table is not populated in the provided text, the page is structured to present financial statistics.

**3. Disc Medicine, Inc. $IRON Shares Acquired by Sio Capital Management LLC**
- Source: MarketBeat | 20251204T090912 | Neutral | Relevance: 64%
- Sio Capital Management LLC significantly increased its stake in Disc Medicine, Inc. ($IRON) by 287.4% in Q2, acquiring an additional 211,276 shares, making it their second-largest holding. Despite strong institutional buying, company insiders, including Director Kevin Bitterman and COO Jonathan Yen-Wen Yu, sold a notable amount of shares in recent months. Analysts have generally become more bullish on Disc Medicine, with several firms raising their price targets, resulting in a "Moderate Buy" consensus rating.

**4. TXO Partners LP $TXO Shares Bought by Wealthedge Investment Advisors LLC**
- Source: MarketBeat | 20251203T050959 | Neutral | Relevance: 61%
- Wealthedge Investment Advisors LLC significantly increased its stake in TXO Partners LP ($TXO) by 65.8%, now owning 88,914 shares valued at $1.34 million. Other institutions also expanded their positions, bringing total institutional ownership to 27.44%. Despite the dividend yield attracting some investors, analyst sentiment is mixed, with a "Moderate Buy" consensus and a $20.50 price target, tempered by sustainability concerns over its 350% payout ratio.

**5. JPMorgan Chase & Co. Buys 175,587 Shares of Molson Coors Beverage Company $TAP**
- Source: MarketBeat | 20251202T103259 | Neutral | Relevance: 60%
- JPMorgan Chase & Co. increased its stake in Molson Coors Beverage Company ($TAP) by 20.4%, acquiring an additional 175,587 shares, bringing their total ownership to 1,036,110 shares valued at approximately $49.83 million. This increase in institutional investment comes as Molson Coors reported an earnings miss for the quarter and set its FY2025 guidance, maintaining an average "Hold" rating from analysts with a target price of $53.59. The company also declared a quarterly dividend of $0.47, reflecting a 4.0% yield.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Piper Sandler | $135 | $155 | -13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Piper Sandler | main | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (+3.2%)
- Berkshire Hathaway, : 7.7% (0.0%)
- Blackrock Inc.: 6.1% (-2.0%)
- Capital World Invest: 3.8% (-43.3%)
- State Street Corpora: 3.8% (-4.2%)

### Key Risks

1. Long-term trend broken: trading 15.2% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $24.3B |
| Beta | 0.46 |
| 52W Range | $126.45 - $228.89 |
| Short Interest | 5.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 11.1 |
| Current P/E | 12.0 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.1% (minimal 5-day change). Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.85x), long-term trend not supportive. MACD histogram positive (1.18), confirming momentum. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.13% (CS: 55) | Neutral |
| RSI_14 | 61.1 | Neutral |
| MACD Histogram | 1.18 | Bullish |
| vs SMA20 | 1.043x | Above |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 0.848x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $138.03
- **Stop Loss:** $132.15 (4.3% risk)
- **Target:** $143.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $11,732.55
- **Portfolio %:** 11.73%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-07 (Est: $2.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.41 | $3.63 | +6.5% |
| 2025Q2 | $3.29 | $3.22 | -2.3% |
| 2025Q1 | $2.27 | $2.63 | +15.9% |
| 2024Q4 | $3.31 | $3.25 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*